Drug-Related Fatality Stops Hepatitis C Trial
Share
Follow Us
Bristol-Myers Drops Hepatitis C Drug After Patient Death
Bloomberg News
By Ryan Flinn on August 24, 2012
Bristol-Myers Squibb Co. (BMY) has abandoned an experimental hepatitis C pill it bought for $2.5 billion earlier this year after one patient died and others were hospitalized while taking the drug in a study.
Bristol-Myers will take a charge of $1.8 billion in the third quarter related to research and development of the therapy, the New York-based company said in a regulatory filing today. The drugmaker suspended testing the medicine, known as BMS-986094, on Aug. 1 after a patient developed heart failure.
Bristol-Myers said yesterday it has discontinued development of the drug, part of a class of medicines called nucleotide polymerase inhibitors, and was consulting with U.S. regulators to assess the treatment’s effects. Along with the death, eight patients suffered from heart and kidney toxicity, the company said in a statement.
Continue reading this entire article:
http://www.businessweek.com/news/2012-08-23/bristol-myers-drops-hepatitis-c-drug-after-patient-death
